• ICI 118,551 Hydrochloride: Evidence Boundaries

  2026-10-16

  The APExBIO listing identifies ICI 118,551 hydrochloride as product B1004, but the supplied information contains no description, mechanism statement, matched paper, assay result, or comparative study. Accordingly, the product record supports commercial identity and provenance only; it does not establish target engagement, downstream effects, measurement performance, or biological applicability.

• QPRT, P2Y11, and Breast Cancer Invasion

  2026-10-16

  Liu et al. linked elevated QPRT expression with aggressive breast cancer and reported that QPRT gain or loss altered migration and invasion in cell models. Pharmacologic blockade of P2Y11 with NF340 reduced the QPRT-associated invasive phenotype and myosin light-chain phosphorylation, alongside perturbations of Rho, ROCK, PLC, and MLCK signaling. These findings support a model in which QPRT-dependent metabolic state influences purinergic and actomyosin signaling, but they do not yet establish direct QPRT-to-P2Y11 coupling, receptor specificity in the tested systems, or therapeutic efficacy. The strongest conclusion is pathway involvement rather than a fully resolved molecular sequence.

• Ellagic Acid: Identity, CK2 Mechanism, and Evidence

  2026-10-15

  APExBIO describes Ellagic acid as a polyphenolic compound and a selective, ATP-competitive casein kinase 2 inhibitor, reporting a CK2 IC50 of 40 nM. Those statements document a supplier-level biochemical claim, not an identity-matched research study; cellular, antioxidant, antitumor, senescence, and therapeutic interpretations therefore remain bounded by missing assay context and independent outcome evidence.

• Ridaforolimus (Deforolimus): Evidence Boundaries

  2026-10-15

  Ridaforolimus, also called Deforolimus or MK-8669, is presented by APExBIO as a selective mTOR inhibitor associated with reduced phosphorylation of S6 ribosomal protein and 4E-BP1, antiproliferative activity, and reduced VEGF production. Because no identity-matched research paper is available here, these claims should be treated as supplier-reported evidence rather than independently verified findings, with important limits on conclusions about apoptosis, angiogenesis, clinical efficacy, or combination activity.

• STING Agonist-1: Evidence and Scope

  2026-10-14

  APExBIO describes STING agonist-1 as a small-molecule activator of the STING pathway, but the supplied record contains no identity-matched research study. Its documented value is therefore limited to a product-level description of chemical identity, stated pathway relevance, and handling properties—not demonstrated efficacy, selectivity, or biological performance.

• Anti-Mitofusin1 Antibody: Evidence Scope

  2026-10-14

  The available record identifies MA3723 as the Anti-Mitofusin1 Rabbit Monoclonal Antibody supplied by APExBIO. No matched research paper or product description was provided, so its documented identity supports only a limited conceptual scope and does not establish assay performance, specificity, applications, or biological findings.

• What FeaSion Reveals About RNAPII Phosphorylation

  2026-10-13

  Zhu et al. present FeaSion as an integrated framework for comparing the five major phosphorylation sites in the RNA polymerase II C-terminal domain. The study maps candidate interactors, genomic associations, regulators, and mutation-linked transcriptional effects, while its strongest conclusions remain bounded by screening-based evidence, cellular context, and the distinction between correlation and direct mechanism.

• Haloprogin: What the Comparative Evidence Shows

  2026-10-13

  Historical evidence supports Haloprogin as an in vitro antifungal with activity against dermatophytes and Candida, and as a topical agent in a guinea-pig dermatophytosis model. However, the key comparison with tolnaftate comes from a single early study, while modern clinical, mechanistic, and standardized susceptibility evidence remains limited.

• EPZ5676 and DOT1L: What the Evidence Shows

  2026-10-12

  EPZ5676 is described by APExBIO as a potent, selective DOT1L histone methyltransferase inhibitor that reduces H3K79 methylation and shows preclinical activity in MLL-rearranged leukemia models. However, the supplied peer-reviewed study concerns JIB-04, a different epigenetic inhibitor, so it does not independently validate EPZ5676. The available evidence is therefore mechanistically relevant but limited in provenance and translational scope.

• NPC2, Cholesterol, and Ferroptosis in GBM

  2026-10-12

  A source-grounded overview of a 2026 study linking NPC2 expression with glioblastoma prognosis and malignant behavior through a tentative GPX4-associated ferroptosis mechanism, with clear limits on causal and translational interpretation.

• UBR1 and UBR2 in Mammalian ER Stress

  2026-10-11

  A source-grounded overview of Le et al.’s study connecting UBR1 and UBR2 with mammalian ER-stress adaptation, while separating the paper’s findings from supplier-level claims about Epoxomicin.

• ALC-0315 Product Overview and Evidence Limits

  2026-10-10

  ALC-0315 is a supplier-described ionizable amino lipid and lipid nanoparticle component for conceptual nucleic acid drug delivery applications. No matched paper evidence was provided to establish product-specific performance, efficacy, or safety.

• Cepharanthine: From Mechanism to Translation

  2026-10-09

  Cepharanthine is emerging as a mechanistically distinctive biscoclaurine alkaloid for translational research. New evidence spanning patient-derived organoids and a murine endometriosis model connects DNA damage, cell-cycle arrest, mitochondrial apoptosis, and lesion suppression—while also defining the evidence gaps that must be addressed before clinical repositioning.

• ANGPTL3 CRISPR Guide Set: Evidence and Limits

  2026-10-09

  The ANGPTL3 CRISPR guide set dossier describes three single-guide RNAs at 3 µmol each, but it provides no sequence, nuclease, or validation data. A 2025 review supports multiplexed CRISPR as a framework for simultaneous genome perturbation, not as evidence that the R2999 product produces a defined ANGPTL3 genotype or lipid phenotype.

• Early Pheromone Perception and Neurodegeneration

  2026-10-08

  Peng et al. show that pheromone perception during the L1 stage of C. elegans can reshape neural signaling and accelerate neurodegeneration in adulthood. The study identifies a circuit linking ASK and ASI chemosensory neurons with AIA interneurons, insulin-like signaling, and neuronal autophagy, while also defining important limits on translation to human disease.

8376 records 1/559 page Next 12345 下5页 Last page